Press releases
The scientific team
Products
-
VAR001
Strategy: Inhibition siRNA gene therapy.
Administration: Subretinal injection.
Therapeutics: Mutation-specific CRX-associated retinopathies. -
VAR002
Strategy: Augmentation AAV gene therapy.
Administration: Subretinal injection.
Therapeutics: CRX-associated retinopathies and other hypomorphic gene retinopathies Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa (RP), Cone-Rod Dystrophy (CoRD) and neuroprotection of other PRs. -
VAR003
Strategy: Inhibition ASO gene therapy.
Administration: Intravitreal injection.
Therakpeutics: CRX-associated retinopathies: Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa (RP), and Cone-Rod Dystrophy (CoRD).